Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models
暂无分享,去创建一个
[1] C. Yun,et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. , 2007, Cancer research.
[2] M. Götte,et al. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. , 2006, Cancer research.
[3] Hoguen Kim,et al. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. , 2006, Journal of the National Cancer Institute.
[4] M. Simpson,et al. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. , 2006, The American journal of pathology.
[5] J S Patton,et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[6] M. Simpson. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. , 2006, The American journal of pathology.
[7] S. Ganesh,et al. Enhanced Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells by Fiber Chimeric Oncolytic Adenoviruses , 2006, Clinical Cancer Research.
[8] D. Ennist,et al. CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer , 2006, Clinical Cancer Research.
[9] J. Bell,et al. Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.
[10] V. Lokeshwar,et al. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. , 2005, Cancer research.
[11] K. Alitalo,et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. , 2005, Cancer research.
[12] Y. Ge,et al. CG0070, a conditionally replicating GM-CSF armed oncolytic adenovirus for the treatment of bladder cancer , 2005 .
[13] S. Karlsson,et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells , 2004, The journal of gene medicine.
[14] Erwin G. Van Meir,et al. Replicative oncolytic adenoviruses in multimodal cancer regimens. , 2003, Human gene therapy.
[15] M. Soloway,et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. , 2003, Cancer research.
[16] Ying Huang,et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. , 2003, Cancer research.
[17] W. Rom,et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. , 2003, Human gene therapy.
[18] A. Csoka,et al. Hyaluronidase reduces human breast cancer xenografts in SCID mice , 2002, International journal of cancer.
[19] M. Simpson,et al. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. , 2002, The American journal of pathology.
[20] W. Rom,et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.
[21] J. Minna,et al. Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer* , 2001, The Journal of Biological Chemistry.
[22] M. Israel,et al. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. , 2001, Cancer research.
[23] M. Israel,et al. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. , 2000, Human gene therapy.
[24] J. Bergelson,et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. , 2000, Cancer research.
[25] N. Rubio,et al. Metastatic burden in nude mice organs measured using prostate tumor PC‐3 cells expressing the luciferase gene as a quantifiable tumor cell marker , 2000, The Prostate.
[26] C. de Lange Davies,et al. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. , 2000, Anticancer research.
[27] C. Chauzy,et al. Human breast‐cancer metastasis formation in a nude‐mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan‐binding sites in metastatic cells , 1999, International journal of cancer.
[28] Y. Chiang,et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.
[29] A. Sagalowsky,et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.
[30] C. Miller,et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.
[31] J. Bergelson,et al. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.
[32] J. Willson,et al. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[33] B. Delpech,et al. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: Comparison between invasive and non‐invasive areas , 1992, International journal of cancer.